Bellus Health announces appointment of Martin Tolar, M.D., Ph.D. to its Board of Directors
BELLUS Health Inc. announced the appointment of Martin Tolar, M.D., Ph.D., to the Board of Directors of the Company, effective immediately.
Dr. Martin Tolar is President and Chief Executive Officer of NormOxys Inc., a private biotechnology company developing oxyrens, a novel class of small molecule drugs which enhance the body's ability to deliver oxygen more efficiently to hypoxic diseased tissues. Before joining NormOxys in 2009, Dr. Tolar was Executive Vice President & Chief Business Officer at CoMentis Inc., a private biotechnology company engaged in the discovery and development of small molecule drugs to treat Alzheimer's disease, macular degeneration and cognition, where he led the company's scientific and business growth and negotiated a landmark collaboration agreement with Astellas Pharma for CoMentis' beta secretase platform, valued at $760 million plus future commercial and product milestones. Dr. Tolar's industry experience also includes seven years at Pfizer Inc., where he served in senior positions in the Clinical Development, Strategic Partnerships and Business Development divisions, and played a leadership role in number of influential business development deals including the acquisition of Rinat Neurosciences and a collaboration transaction with TransTech Pharma. Dr. Tolar serves on the board of directors of Suven Life Sciences Ltd, a public biopharmaceutical company based in Hyderabad, India.
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
